JP Morgan Chase
SONN

JP Morgan Chase’s Sonnet BioTherapeutics SONN Stock Holding History

JP Morgan Chase’s Portfolio SONN Stock Details SONN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-7,537
Closed -$34.5K – 7747
2025
Q3 		$34.5K Buy
+7,537
New +$33.4K ﹤0.01% 6350
2024
Q1 		– Sell
-2
Closed -$33 – 7853
2023
Q4 		$33 Buy
+2
New +$27 ﹤0.01% 7266
2023
Q3 		– Sell
-170
Closed -$14.7K – 7713
2023
Q2 		$14.7K Buy
+170
New +$12K ﹤0.01% 5985
2022
Q2 		– Sell
-6
Closed -$5K – 6858
2022
Q1 		$5K Buy
+6
New +$5.08K ﹤0.01% 6327
2020
Q4 		– Hold
0
– – – 5905
2020
Q3 		– Hold
0
– – – 5750
2020
Q2 		– Hold
0
– – – 5678
2016
Q1 		– Hold
0
– – – 4917
2015
Q4 		– Hold
0
– – – 4797

Other funds holding SONN

FAM
Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return

JP Morgan Chase's SONN Position: Q4 2025 in Review

JP Morgan Chase sold out of Sonnet BioTherapeutics (SONN) in Q4 2025, closing a stake of 7,537 shares — an estimated $34.5K sold.

JP Morgan Chase first reported a position in SONN in Q1 2022 and held it in 4 quarters. The position peaked at $34.5K in Q3 2025. 1 fund tracked by Wall St. Rank holds SONN as of Q4 2025.

  • JP Morgan Chase reported no remaining Sonnet BioTherapeutics position as of Q4 2025 after selling out during the quarter.
  • JP Morgan Chase sold 7,537 Sonnet BioTherapeutics shares in Q4 2025, an estimated $34.5K.
  • JP Morgan Chase first reported a position in Sonnet BioTherapeutics in Q1 2022 and held it in 4 quarters.
  • JP Morgan Chase's Sonnet BioTherapeutics position peaked at $34.5K in Q3 2025.
  • 1 fund tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q4 2025.

Based on JP Morgan Chase's 13F filing for Q4 2025, filed 11 Feb 2026.